Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.
The Latest Insights
ICER’s Latest: A draft evidence report on new treatment for Beta Thalassemia
On April 13, 2022, ICER released its draft evidence report, “Betibeglogene Autotemcel for Beta Thalassemia.” This is the first step in ICER’s review process; ICER is scheduled to release a final report on this treatment in July 2022. Beta thalassemia is a disease...
Businesses With High-Value, Low-Cost Health Insurance Receive First-Ever Health Plan Hero Awards
Six small businesses from across the country were among the first companies ever to receive a national award for their innovative, outstanding employer-sponsored health program. The companies received the 2022 Health Plan Hero award in a ceremony recently held in the...
More of the Same: ICER’s latest salvo on rare diseases
Earlier this month, ICER released a white paper titled “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.” If you have been monitoring ICER’s work over the years, the paper likely matches your expectations. Ostensibly, the...
Event: Health Plan Heroes Awards Program and Roundtable
Patients Rising's first annual Health Plan Heroes event will honor companies that have adopted innovative benefit design for their employees. In addition, a panel of experts will have a roundtable discussion on ways for employers to enhance patient access to care as...
Last Word: ICER’s Premature Assessment of New Treatment for Type 2 Diabetes
In mid-February, ICER released a Final Evidence Report on tirzepatide, a new insulin treatment for Type 2 diabetes (T2D). After following its normal process - including preliminary drafts and public comments - ICER concluded the new medication works better than the...
ICER’s Latest Backtracking Illuminates Inconsistent Policies & Practices
Inconsistency at ICER is nothing new. For years, they have been releasing their own version of proprietary value assessments about new drugs and treatments. They've set standard practices and protocols for their assessment process and have updated them over the years....
Get Updates in Your Inbox
Sign Up. Stay Informed.